Biotechnology · West Conshohocken, Pennsylvania, United States
$563.00
-0.33% (-$1.87)2026-07-09
Smart-Money SignalNeutral · 49/100— Insiders are net sellers over 90 days (-$3.9M, 14 sales vs 6 buys)
Revenue$311.3M
Net Income-$94.4M
EPS$-3.25
Market Cap$13.0B
Price Performance
Historical data including institutional events
Company Profile
W
William Sibold
CEO & Executive Director
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
